No phaseCompleted

Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients

Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients: A Prospective Analysis

Sponsor
Universidade do Porto (Academic or other)
Enrollment
55 enrolled
Conditions
Heart Failure; Anemia
Interventions
Oral iron supplementation
Ages
adults, older adults
Registry
NCT07708025

Full record on ClinicalTrials.gov

From the registry

People with heart failure often have anemia caused by low iron levels. Ongoing inflammation in heart failure can impair iron absorption, making oral iron therapy less effective. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are medications used to treat heart failure. In addition to their cardiovascular benefits, these drugs may improve iron metabolism and support red blood cell production. This study evaluates whether patients with heart failure and iron deficiency anemia who are receiving SGLT2i therapy respond to treatment with oral iron. Participants receive oral iron for three to four months, followed by a short period without treatment. Blood tests are used to assess changes in hemoglobin levels. The objective of this study is to determine whether treatment with SGLT2i enhances the response to oral iron in patients with heart failure and iron deficiency anemia.

Primary outcomes

  • Change in Hemoglobin Levels

History

  1. Last registry update

  2. Registered

  3. Study completion

  4. Primary completion

  5. Started